Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 14.17
(-0.14%)
USD 14.17
(-0.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -44.43 Million USD | -50.61% |
| 2022 | -38.72 Million USD | 47.56% |
| 2021 | -54.97 Million USD | 53.92% |
| 2020 | -121.68 Million USD | -58.69% |
| 2019 | -76.36 Million USD | -35.37% |
| 2018 | -56.25 Million USD | -74.78% |
| 2017 | -32.3 Million USD | -63.56% |
| 2016 | -19.89 Million USD | -125.78% |
| 2015 | -8.8 Million USD | -234.25% |
| 2014 | -2.63 Million USD | -373.41% |
| 2013 | -556.52 Thousand USD | -885869.91% |
| 2012 | -62.81 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.47 Million USD | 4.87% |
| 2024 Q2 | -10.78 Million USD | 3.44% |
| 2023 Q1 | -17.29 Million USD | -56.12% |
| 2023 FY | - USD | -50.61% |
| 2023 Q4 | -9.95 Million USD | -7.39% |
| 2023 Q3 | -9.27 Million USD | -15.47% |
| 2023 Q2 | -8.02 Million USD | 53.59% |
| 2022 Q4 | -11.07 Million USD | -44.45% |
| 2022 Q3 | -7.67 Million USD | -335.88% |
| 2022 Q2 | -1.75 Million USD | 77.67% |
| 2022 Q1 | -7.88 Million USD | 21.33% |
| 2022 FY | - USD | 47.56% |
| 2021 Q1 | -15 Million USD | 26.56% |
| 2021 Q2 | -16.47 Million USD | -9.81% |
| 2021 Q3 | -13.51 Million USD | 17.95% |
| 2021 FY | - USD | 53.92% |
| 2021 Q4 | -10.01 Million USD | 25.88% |
| 2020 Q3 | -33.16 Million USD | 13.08% |
| 2020 Q2 | -38.15 Million USD | -29.12% |
| 2020 Q1 | -29.55 Million USD | -8.75% |
| 2020 FY | - USD | -58.69% |
| 2020 Q4 | -20.42 Million USD | 38.41% |
| 2019 Q3 | -24.71 Million USD | -1332.19% |
| 2019 FY | - USD | -35.37% |
| 2019 Q1 | -26.23 Million USD | -48.8% |
| 2019 Q4 | -27.17 Million USD | -9.95% |
| 2019 Q2 | 2 Million USD | 107.65% |
| 2018 Q2 | -12.32 Million USD | -4.92% |
| 2018 Q1 | -11.74 Million USD | -8.46% |
| 2018 FY | - USD | -74.78% |
| 2018 Q4 | -17.63 Million USD | -19.18% |
| 2018 Q3 | -14.79 Million USD | -20.01% |
| 2017 Q3 | -6.77 Million USD | 6.49% |
| 2017 FY | - USD | -63.56% |
| 2017 Q2 | -7.24 Million USD | 2.14% |
| 2017 Q4 | -10.83 Million USD | -59.82% |
| 2017 Q1 | -7.4 Million USD | 1.83% |
| 2016 Q3 | -5.29 Million USD | -27.07% |
| 2016 FY | - USD | -125.78% |
| 2016 Q4 | -7.54 Million USD | -42.39% |
| 2016 Q2 | -4.16 Million USD | -45.35% |
| 2016 Q1 | -2.86 Million USD | -15.6% |
| 2015 Q4 | -2.48 Million USD | -10.84% |
| 2015 Q2 | -2.55 Million USD | -67.13% |
| 2015 Q1 | -1.52 Million USD | -22.06% |
| 2015 FY | - USD | -234.25% |
| 2015 Q3 | -2.23 Million USD | 12.39% |
| 2014 Q4 | -1.25 Million USD | -54.2% |
| 2014 FY | - USD | -373.41% |
| 2014 Q3 | -812.54 Thousand USD | -75.29% |
| 2014 Q2 | -463.53 Thousand USD | -338.96% |
| 2014 Q1 | -105.6 Thousand USD | 61.77% |
| 2013 Q3 | -45.21 Thousand USD | -240.41% |
| 2013 Q1 | -3.96 USD | 0.0% |
| 2013 Q2 | -13.28 Thousand USD | -335075.37% |
| 2013 Q4 | -276.19 Thousand USD | -510.83% |
| 2013 FY | - USD | -885869.91% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 72.758% |
| Dynavax Technologies Corporation | 9.66 Million USD | 559.722% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 145.223% |
| Perrigo Company plc | 646.2 Million USD | 106.877% |
| Illumina, Inc. | -608 Million USD | 92.691% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.411% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 90.103% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.606% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 101.365% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 57.187% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.955% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -19.188% |
| Waters Corporation | 1.02 Billion USD | 104.347% |
| Biogen Inc. | 2.37 Billion USD | 101.869% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 49.173% |
| Evolus, Inc. | -41.81 Million USD | -6.282% |
| Adicet Bio, Inc. | -136.53 Million USD | 67.454% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 62.23% |
| bluebird bio, Inc. | -167.16 Million USD | 73.417% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 70.397% |
| FibroGen, Inc. | -261.4 Million USD | 83.001% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 102.65% |
| Homology Medicines, Inc. | -47.75 Million USD | 6.951% |
| Geron Corporation | -174.78 Million USD | 74.576% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 80.521% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 51.741% |
| Myriad Genetics, Inc. | -67.8 Million USD | 34.459% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 55.928% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 91.224% |
| Zoetis Inc. | 3.68 Billion USD | 101.206% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 12.132% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 103.817% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 114.321% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.965% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -23.155% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 80.681% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 83.294% |
| Verastem, Inc. | -83.16 Million USD | 46.569% |
| Nektar Therapeutics | -243.1 Million USD | 81.721% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 80.25% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 49.495% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 89.882% |
| OPKO Health, Inc. | -65.51 Million USD | 32.174% |
| Exelixis, Inc. | 196.6 Million USD | 122.602% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 110.679% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 141.022% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 20.301% |
| uniQure N.V. | -253.1 Million USD | 82.443% |
| Imunon, Inc. | -20.78 Million USD | -113.82% |
| Blueprint Medicines Corporation | -474.61 Million USD | 90.637% |
| Insmed Incorporated | -654.73 Million USD | 93.213% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 109.832% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 87.137% |
| TG Therapeutics, Inc. | 26.1 Million USD | 270.256% |
| Incyte Corporation | 919.42 Million USD | 104.833% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 91.206% |